Exelon(rivastigmine)
Exelon, Nimvastid, Prometax, Rivastigmine (rivastigmine) is a small molecule pharmaceutical. Rivastigmine was first approved as Exelon on 1998-05-11. It is used to treat alzheimer disease in the USA. It has been approved in Europe to treat alzheimer disease, dementia, and parkinson disease. The pharmaceutical is active against cholinesterase and acetylcholinesterase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Exelon, Rivastigmine (discontinued: Exelon, Rivastigmine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| exelon | New Drug Application | 2024-05-08 |
| rivastigmine | ANDA | 2024-09-21 |
| rivastigmine tartrate | ANDA | 2024-10-24 |
| rivastigmine transdermal system | ANDA | 2025-01-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alzheimer disease | EFO_0000249 | D000544 | F03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
108 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 4 | 13 | 20 | 16 | 54 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 2 | 7 | 6 | 7 | 22 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | 4 | 8 | 2 | 14 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 3 | 6 | — | 9 |
| Delirium | D003693 | — | R41.0 | 1 | 3 | 3 | 3 | — | 9 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 2 | 1 | 6 |
| Cognition disorders | D003072 | — | — | — | — | 1 | 2 | 2 | 5 |
| Emergence delirium | D000071257 | — | — | 1 | 1 | 1 | 2 | — | 4 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | 2 | 1 | — | 3 |
| Brain injuries | D001930 | — | S06.9 | — | — | 2 | 1 | — | 3 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | 1 | 1 | — | — | 2 |
| Vascular dementia | D015140 | — | F01 | — | — | 2 | — | — | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | 1 | — | — | 1 |
| Apathy | D057565 | — | — | — | — | 1 | — | — | 1 |
| Hypokinesia | D018476 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | 1 | — | — | 1 | 2 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | 1 | 1 | — | — | 1 | 2 |
| Syndrome | D013577 | — | — | 1 | 1 | — | — | 1 | 2 |
| Anticholinergic syndrome | D064807 | — | — | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | — | 3 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | — | — | — | 2 | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 3 | — | — | — | — | 3 |
| Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | 1 | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy aging | D000073656 | — | — | — | — | — | — | 2 | 2 |
| Brain diseases | D001927 | — | G93.40 | — | — | — | — | 2 | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 2 | 2 |
| Mixed dementias | D000093902 | — | — | — | — | — | — | 1 | 1 |
| Late onset disorders | D000067562 | — | — | — | — | — | — | 1 | 1 |
| Deep brain stimulation | D046690 | — | — | — | — | — | — | 1 | 1 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | — | — | — | 1 | 1 |
| Tauopathies | D024801 | — | — | — | — | — | — | 1 | 1 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rivastigmine |
| INN | rivastigmine |
| Description | Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a neuroprotective agent and a cholinergic drug. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+). |
| Classification | Small molecule |
| Drug class | cholinesterase inhibitors (physostigmine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 123441-03-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL636 |
| ChEBI ID | 8874 |
| PubChem CID | 77991 |
| DrugBank | DB00989 |
| UNII ID | PKI06M3IW0 (ChemIDplus, GSRS) |
Target
Agency Approved
BCHE
BCHE
ACHE
ACHE
Organism
Homo sapiens
Gene name
BCHE
Gene synonyms
CHE1
NCBI Gene ID
Protein name
cholinesterase
Protein synonyms
Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, cholinesterase (serum) 2, cholinesterase 1, Pseudocholinesterase
Uniprot ID
Mouse ortholog
Bche (12038)
cholinesterase (Q543J3)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Exelon – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rivastigmine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,942 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,407 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use